Bamlanivimab

DRUG8 trials

Sponsors

Eli Lilly and Company, Daniel Griffin, Fraser Health, Sohail Rao, University of Milano Bicocca

Conditions

COVID-19Covid19SARS-CoV2

Phase 2

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

CompletedNCT04634409

Eli Lilly and CompanyCOVID-19

Start: 2020-10-29End: 2021-10-18Updated: 2022-07-01

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

CompletedNCT04701658

Eli Lilly and CompanyCOVID-19

Start: 2021-02-01End: 2021-06-22Updated: 2021-11-16

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Sohail RaoCovid19

Start: 2020-11-20End: 2023-01-31Target: 1000Updated: 2022-03-29

Phase 3

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

CompletedNCT04497987

Eli Lilly and CompanyCOVID-19, SARS-CoV2

Start: 2020-08-02End: 2021-05-20Updated: 2022-02-04

Phase 4

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

TerminatedNCT04656691

Daniel GriffinCovid19

Start: 2021-01-04End: 2021-04-18Updated: 2022-03-18

A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19

Fraser HealthCovid19

Start: 2021-03-17End: 2021-12-31Target: 576Updated: 2021-08-26

Unknown Phase

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Eli Lilly and CompanyCOVID-19

Updated: 2023-10-02

COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

CompletedNCT05268601

University of Milano BicoccaCOVID-19

Start: 2021-10-14End: 2023-12-22Updated: 2025-03-30

Related Papers

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

2024-09-041 citations

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.

2024-01-305 citations

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019

Open Forum Infectious Diseases2022-02-0242 citations

Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial.

2021-11-066 citations

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.

2021-08-1029 citations

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

JAMA2021-06-03208 citations